Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo: Smith Collection/Gado/Getty Images
Gummy candies, soft drinks, dog treats, body lotions — these days, everything under the sun is available with CBD, or cannabidoil, an ingredient derived from a non-psychotropic part of the marijuana plant.
The big picture: While everyone from Kim Kardashian to Gwyneth Paltrow relishes the supposedly relaxing qualities of CBD, the FDA is still evaluating the therapeutic claims of the industry.
The numbers that matter: In 2018, the U.S. cannabinoid market, including high-THC products with small amounts of CBD, totaled about $10.5 billion, according to a report by Arcview, a cannabis research and investment group.
- By 2024, the market is projected to grow to $44.8 billion.
- That tops U.S. legal spending on cannabis (medical and recreational), which Arcview says was $9.8 billion in 2018 and could reach $30 billion in 2024.
- Caveat: These markets are difficult to track accurately, so the numbers should be treated as estimates.
What we're hearing: “Over time, there is a sense by some people in the industry that [CBD] is a bigger opportunity than marijuana and THC around the globe,” Chris Walsh, president and founding editor of MJBizDaily, tells Axios.
- Buzzy categories include beauty products like skin care and pet products, Walsh says.
- Big pharma and large convenience chains are driving a lot of the market’s growth.
- But a current lack of oversight and regulation means that low-quality (or even scammy) products can discourage consumers who have bad experiences.
Go deeper: